RxDoctor Payments Data

Matthew McElroy, PA

Family Medicine · Black Canyon City, AZNPI 1225685118

Payments from drug & device makers

$3,508in general payments, 2019–2025

Across 166 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$965
  • AbbVie$282
  • Amgen$272
  • GSK$258
  • Exact Sciences$217
  • Novo Nordisk$205
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,508100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,508 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$716
Medicare patients
48
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$87,643
FarxigaDapagliflozin Propanediol72$73,242
JardianceEmpagliflozin24$30,942
EliquisApixaban30$30,353
TrulicityDulaglutide21$30,273
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$25,918
WegovySemaglutide11$24,031
MounjaroTirzepatide21$22,921
Repatha SureclickEvolocumab31$19,740
Xigduo XrDapaglifloz Propaned/Metformin20$19,036
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,011
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$13,371
BelbucaBuprenorphine Hcl11$11,168
DapagliflozinDapagliflozin Propanediol16$10,128
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$10,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$205$119,845102 claims
AstraZenecaFarxiga, Breztri Aerosphere$965$88,25296 claims
Lilly USA, LLCTrulicity, Mounjaro$112$53,19542 claims
PfizerEliquis$123$30,35330 claims
GSKTrelegy Ellipta$258$25,91822 claims
AbbVieLinzess$282$8,80812 claims
Astellas Pharma US IncMyrbetriq$23$8,37311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Black Canyon City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →